Treating High Cholesterol Could Become A One-And-Done Treatment [Forbes]
Beam Therapeutics Inc. (BEAM)
US:NYSE Investor Relations:
beamsuntory.com/about/shareholder-information/reports
Company Research
Source: Forbes
Since their introduction in the 1980s, statins have been a gamechanger in lowering the risk of heart attacks and strokes for millions of people with high cholesterol. They work by blocking a liver enzyme that makes LDL cholesterol, the so-called “bad” cholesterol. This in turn reduces the buildup of plaque in arteries. It's no exaggeration to say that statins revolutionized the prevention and management of cardiovascular disease, the leading cause of death in the developed world. That said, statins do have some drawbacks: They need to be taken every day, which requires patients to remember and comply with the regimen. They are not curative, and they can come with troublesome side effects, like muscle aches and liver enzyme changes. But what if there was a one-time treatment for patients with high cholesterol that safely tweaked their underlying biology and permanently lowered their heart attack risk? Now, some forty years after the introduction of statins, we may be on the brin
Show less
Read more
Impact Snapshot
Event Time:
BEAM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BEAM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BEAM alerts
High impacting Beam Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
BEAM
News
- Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal [Seeking Alpha]Seeking Alpha
- Beam Therapeutics (BEAM) Earnings Transcript [Yahoo! Finance]Yahoo! Finance
- Beam Therapeutics (NASDAQ:BEAM) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Beam Therapeutics (NASDAQ:BEAM) is now covered by analysts at Evercore ISI. They set an "outperform" rating on the stock.MarketBeat
- Gene Editing Pioneer David Liu: Fixing Baby's Rare Disease Heralds New Medical Era [Forbes]Forbes
BEAM
Earnings
- 11/4/25 - Miss
BEAM
Sec Filings
- 11/5/25 - Form SCHEDULE
- 11/4/25 - Form 10-Q
- 11/4/25 - Form 8-K
- BEAM's page on the SEC website